The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists.

Abstract

OBJECTIVES:

Several observational studies suggest an association between treatment with ergoline-derived dopamine agonists and valvular regurgitation. In this article, we present an overview of the literature and conduct a meta-analysis.

METHODS:

Observational studies addressing the frequency of moderate or severe valvular regurgitation among ergoline-treated patients with Parkinson's disease were considered for a meta-analysis. Pooled risk estimates and the risk of increased pulmonary artery pressure were calculated.

RESULTS:

The pooling of data from well-designed observational studies documented that both pergolide (RR = 3.05 [1.71-5.44]) and cabergoline (RR = 6.38 [3.17-12.81]) represent a substantially increased risk of developing moderate to severe valvular regurgitation. In addition, pergolide, but not cabergoline, was associated with an increase in pulmonary artery pressure.

CONCLUSIONS:

The present meta-analysis confirmed a statistically significant association between pergolide and cabergoline treatment and the risk of moderate to severe valvular regurgitation. An association between bromocriptine and valvular regurgitation cannot be entirely ruled out.

• Authors: Vibeke Guldbrand Rasmussen, Karen Østergaard, Erik Dupont, Steen Hvitfeldt Poulsen
• Journal: Movement disorders : official journal of the Movement Disorder Society (Mov Disord) Vol. 26 Issue 5 Pg. 801-6 (Apr 2011) ISSN: 1531-8257 [Electronic] United States
• PMID: 21671508 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Dopamine Agonists

Topics

• Databases, Factual (statistics & numerical data)
• Dopamine Agonists (adverse effects)
• Heart Valve Diseases (chemically induced)
• Humans
• Models, Statistical
• Observation
• Parkinson Disease (drug therapy)
• Risk Factors